

$\frac{100}{2025-2026}$

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM



Letter From Senior Leadership



Dear Prospective Fellow,

On behalf of Bristol Myers Squibb (BMS) and the Ernest Mario School of Pharmacy, we would like to thank you for your interest in the Post-Doctoral Pharmaceutical Industry Fellowship Program. The pharmaceutical industry provides many exciting and dynamic opportunities, and the same is true at BMS in particular.

BMS truly differentiates itself by combining the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company. We never give up in our search for the next innovation that could mean new hope for patients who are urgently seeking new treatment options today. Constantly pushing the boundaries of scientific excellence, our medicines help millions of people in their fight against serious diseases. Focused on addressing areas of significant unmet medical need, we have exciting development programs in areas such as oncology, hematology, immunology, neuroscience, and cardiovascular diseases.

We recognize the importance of social responsibility and the innovative medicines we create. Our belief that "the priceless ingredient of every product is the integrity of its maker," shines through in how we hold ourselves to the highest standard of integrity. We are not only committed to making a difference in the lives of patients, but also in the global communities where we operate.

BMS places an equal commitment to the development of the individuals who work with us. To meet our mission of helping patients prevail over serious diseases, we are committed to developing a workforce that is diverse, inclusive and representative of the communities in which we operate. We want employees to bring their authentic selves to work and to use their perspectives to contribute in a unique and meaningful way to our mission. We champion these efforts at the highest levels of our organization to ensure our people are engaged and empowered.

Over the past 30 years, we have been creating a best-in-class fellowship program devoted to preparing unique and highly motivated individuals, like yourself, for a rewarding and successful career in our industry.

On behalf of everyone at BMS, we invite you to strongly consider joining our community of people working together to transform the lives of patients through one of the fellowships we offer with Rutgers, Ernest Mario School of Pharmacy. We wish you the best of luck during the recruitment process.

Sincerely, Chris Boerner, Ph.D Board Chair and Chief Executive Officer

Table of Contents

101 = E

PROGRAM DESCRIPTION Marketed Products & Innovative Pipeline	ABOUT BRISTOL MYERS SQUIBB	4
BMS Fellowship Campus locations	PROGRAM DESCRIPTION	
Post-Doctoral Program Governance. 7-8 RECRUITING OPPORTUNITIES. 9 COMMERCIAL 10 US Market Access. 12 US Market Access. 12 US & WW CAR-T Marketing & Commercial. 13 CLINICAL DEVELOPMENT 14 Global Drug Developement. 15 MEDICAL 16 WW Oncology Medical Education & US Oncology Pan Tumor Medical Strategy. 17 US & WW Immunology Medical Strategy. 17 WX & US Oncology Medical Strategy. 19 WW & US Oncology Medical Strategy. 20 WW Cardiovascular Medical Strategy. 20 WW Cardiovascular Medical Strategy. 20 WW Cardiovascular Medical Affairs. 21 US Mununology and Neuroscience Medical Communications & Medical Strategy. 22 US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG) 23 US Commercial Regulatory Strategy. 26 Global Regulatory Strategy. 26 US Commercial Regulatory Affairs: Advertising & Promotion. 27 BMS RESIDENCY 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency. 29	Marketed Products & Innovative Pipeline	5
RECRUITING OPPORTUNITIES		
COMMERCIAL 10 Commercial Business Insights & Analytics. 11 US Market Access. 12 US & WW CAR-T Marketing & Commercial. 13 CLINICAL DEVELOPMENT 14 Global Drug Developement. 15 MEDICAL 16 WW Oncology Medical Education & US Oncology Pan Tumor Medical Strategy. 17 US Cardiovascular Medical Strategy. 17 US Cardiovascular Medical Strategy. 19 WW & US Oncology Medical Strategy. 19 WW & US Oncology Medical Strategy. 20 WW & US Oncology Medical Strategy. 21 WW Immunology Medical Strategy. 22 US a WW Immunology Medical Strategy. 22 US Multimunology and Neuroscience Medical Communications & Medical Strategy. 22 US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG) 23 US & WW Hematology Medical Affairs. 24 REGULATORY 25 Global Regulatory Strategy. 26 US Commercial Regulatory Affairs: Advertising & Promotion. 27 BMS RESIDENCY. 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency. <	Post-Doctoral Program Governance	7-8
Commercial Business Insights & Analytics 11 US Market Access 12 US & WW CAR-T Marketing & Commercial 13 CLINICAL DEVELOPMENT 14 Global Drug Developement 15 MEDICAL 16 WW Oncology Medical Education & US Oncology Pan Tumor Medical Strategy 17 US Cardiovascular Medical Strategy & Field Medical Sciences 18 US & WW Immunology Medical Strategy. 19 WW & US Oncology Medical Strategy. 20 WW & US Oncology Medical Strategy. 20 WW V ardiovascular Medical Strategy. 20 WW & US Oncology Medical Strategy. 20 WW & US Oncology Medical Strategy. 20 WW Immunology and Neuroscience Field Medical Sciences 21 WW Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG) 23 US & WW Hematology Medical Affairs. 24 REGULATORY 25 Global Regulatory Strategy. 26 US Commercial Regulatory Affairs: Advertising & Promotion. 27 BMS RESIDENCY 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency. 29 NON-RECRUITING FELLOWSHI		9
US Market Access	COMMERCIAL	10
US & WW CAR-T Marketing & Commercial 13 CLINICAL DEVELOPMENT 14 Global Drug Developement 15 MEDICAL 16 WW Oncology Medical Education & US Oncology Pan Tumor Medical Strategy 17 US & Cardiovascular Medical Strategy & Field Medical Sciences 18 US & WW Immunology Medical Strategy 19 WW & US Oncology Medical Strategy 20 WW Cardiovascular Medical Affairs 21 WW Cardiovascular Medical Affairs 21 WW Immunology and Neuroscience Medical Communications & Medical Strategy 22 US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG) 23 US & WW Hemotology Medical Affairs 24 REGULATORY 25 Global Regulatory Strategy 26 US Commercial Regulatory Affairs: Advertising & Promotion 27 BMS RESIDENCY 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency 29 NON-RECRUITING FELLOWSHIPS 30 LEADERSHIP SPOTLIGHT 31 RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB 32-33 BRISTOL MYERS SQUIBB COMPONENT 34	Commercial Business Insights & Analytics	11
CLINICAL DEVELOPMENT 14 Global Drug Developement 15 MEDICAL 16 WW Oncology Medical Education & US Oncology Pan Tumor Medical Strategy 17 US Cardiovascular Medical Strategy & Field Medical Sciences 18 US & WW Immunology Medical Strategy 19 WW & US Oncology Medical Strategy 20 WW Cardiovascular Medical Affairs 21 WW Immunology and Neuroscience Medical Communications & Medical Strategy 22 US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG) 23 US & WW Hematology Medical Affairs 24 REGULATORY 25 Global Regulatory Strategy. 26 US Commercial Regulatory Affairs: Advertising & Promotion. 27 BMS RESIDENCY 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency. 29 NON-RECRUITING FELLOWSHIPS 30 LEADERSHIP SPOTLIGHT 31 RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB 32-33 BRIST		
Global Drug Developement. 15 MEDICAL 16 WW Oncology Medical Education & US Oncology Pan Tumor Medical Strategy. 17 US Cardiovascular Medical Strategy & Field Medical Sciences. 18 US & WW Immunology Medical Strategy. 19 WW & US Oncology Medical Strategy. 19 WW & US Oncology Medical Strategy. 20 WW Cardiovascular Medical Affairs. 21 WW Immunology and Neuroscience Medical Communications & Medical Strategy. 22 US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG) 23 US & WW Hematology Medical Affairs. 24 REGULATORY 25 Global Regulatory Strategy. 26 US Commercial Regulatory Affairs: Advertising & Promotion. 27 BMS RESIDENCY. 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency. 29 NON-RECRUITING FELLOWSHIPS. 30 LEADERSHIP SPOTLIGHT. 31 RUTGERS FELLOWSHIPS LOWPONENT 34	US & WW CAR-T Marketing & Commercial	13
MEDICAL 16 WW Oncology Medical Education & US Oncology Pan Tumor Medical Strategy. 17 US Cardiovascular Medical Strategy & Field Medical Sciences. 18 US & WW Immunology Medical Strategy. 19 WW & US Oncology Medical Strategy. 19 WW & US Oncology Medical Strategy. 20 WW Cardiovascular Medical Affairs. 21 WW Immunology and Neuroscience Medical Communications & Medical Strategy. 22 US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG). 23 US & WW Hematology Medical Affairs. 24 REGULATORY 25 Global Regulatory Strategy. 26 US Commercial Regulatory Affairs: Advertising & Promotion. 27 BMS RESIDENCY. 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency. 29 NON-RECRUITING FELLOWSHIPS 30 LEADERSHIP SPOTLIGHT 31 RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB 32-33 BRISTOL MYERS SQUIBB COMPONENT 34		14
WW Oncology Medical Education & US Oncology Pan Tumor Medical Strategy.	Global Drug Developement	15
US Cardiovascular Medical Strategy & Field Medical Sciences. IS & WW Immunology Medical Strategy. WW & US Oncology Medical Strategy. WW Cardiovascular Medical Affairs. US & munology and Neuroscience Medical Communications & Medical Strategy. US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG). US & WW Hematology Medical Affairs. REGULATORY. Global Regulatory Strategy. US Commercial Regulatory Affairs: Advertising & Promotion. 27 BMS RESIDENCY. BMS RESIDENCY. NON-RECRUITING FELLOWSHIPS. 30 LEADERSHIP SPOTLIGHT. RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB. 32-33 BRISTOL MYERS SQUIBB COMPONENT. 34	MEDICAL	16
US & WW Immunology Medical Strategy	WW Oncology Medical Education & US Oncology Pan Tumor Medical Strategy	17
WW & US Oncology Medical Strategy. 20 WW Cardiovascular Medical Affairs. 21 WW Immunology and Neuroscience Medical Communications & Medical Strategy. 22 US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG). 23 US & WW Hematology Medical Affairs. 24 REGULATORY 25 Global Regulatory Strategy. 26 US Commercial Regulatory Affairs: Advertising & Promotion. 27 BMS RESIDENCY 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency. 29 NON-RECRUITING FELLOWSHIPS 30 LEADERSHIP SPOTLIGHT. 31 RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB. 32-33 BRISTOL MYERS SQUIBB COMPONENT 34	US Cardiovascular Medical Strategy & Field Medical Sciences	18
WW Cardiovascular Medical Affairs. 21 WW Immunology and Neuroscience Medical Communications & Medical Strategy. 22 US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG) 23 US & WW Hematology Medical Affairs. 24 REGULATORY 25 Global Regulatory Strategy. 26 US Commercial Regulatory Affairs: Advertising & Promotion. 27 BMS RESIDENCY. 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency. 29 NON-RECRUITING FELLOWSHIPS. 30 LEADERSHIP SPOTLIGHT. 31 RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB 32-33 BRISTOL MYERS SQUIBB COMPONENT 34	US & WW Immunology Medical Strategy	19
WW Immunology and Neuroscience Medical Communications & Medical Strategy. 22 US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG) 23 US & WW Hematology Medical Affairs. 24 REGULATORY 25 Global Regulatory Strategy. 26 US Commercial Regulatory Affairs: Advertising & Promotion. 27 BMS RESIDENCY 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency. 29 NON-RECRUITING FELLOWSHIPS 30 LEADERSHIP SPOTLIGHT 31 RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB 32-33 BRISTOL MYERS SQUIBB COMPONENT 34		
US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG)		
US & WW Hematology Medical Affairs		
REGULATORY 25 Global Regulatory Strategy. 26 US Commercial Regulatory Affairs: Advertising & Promotion. 27 BMS RESIDENCY 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency. 29 NON-RECRUITING FELLOWSHIPS 30 LEADERSHIP SPOTLIGHT 31 RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB. 32-33 BRISTOL MYERS SQUIBB COMPONENT 34		
Global Regulatory Strategy. 26 US Commercial Regulatory Affairs: Advertising & Promotion. 27 BMS RESIDENCY. 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency. 29 NON-RECRUITING FELLOWSHIPS. 30 LEADERSHIP SPOTLIGHT. 31 RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB. 32-33 BRISTOL MYERS SQUIBB COMPONENT 34	US & WW Hematology Medical Affairs	24
US Commercial Regulatory Affairs: Advertising & Promotion	REGULATORY	25
BMS RESIDENCY 28 Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency. 29 NON-RECRUITING FELLOWSHIPS 30 LEADERSHIP SPOTLIGHT 31 RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB 32-33 BRISTOL MYERS SQUIBB COMPONENT 34	Global Regulatory Strategy	
Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency	US Commercial Regulatory Affairs: Advertising & Promotion	27
NON-RECRUITING FELLOWSHIPS 30 LEADERSHIP SPOTLIGHT 31 RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB 32-33 BRISTOL MYERS SQUIBB COMPONENT 34	BMS RESIDENCY	
LEADERSHIP SPOTLIGHT .31 RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB .32-33 BRISTOL MYERS SQUIBB COMPONENT .34	Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency	29
RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB	NON-RECRUITING FELLOWSHIPS	30
BRISTOL MYERS SQUIBB COMPONENT	LEADERSHIP SPOTLIGHT	
	RUTGERS FELLOWSHIP ALUMNI AT BRISTOL MYERS SQUIBB	
RUTGERS COMPONENT	BRISTOL MYERS SQUIBB COMPONENT	
	RUTGERS COMPONENT	

100

-

(III Bristol Myers Squibb"

About Bristol Myers Squibb

Our Mission

To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Our Commitment

To our patients and customers, employees, global communities, shareholders, environment and other stakeholders, we promise to act on our belief that the priceless ingredient of every product is the integrity of its maker. We operate with effective governance and high standards of ethical behavior. We seek transparency and dialogue with our stakeholders to improve our understanding of their needs. We take our commitment to economic, social and environmental sustainability seriously, and extend this expectation to our partners and suppliers. As a responsible corporate citizen, we seek to actively improve the health of the communities where we live, work and serve. Around the globe, we promote health equity and seek to promote the health outcomes of populations disproportionately affected by serious disease. We believe our diverse and inclusive culture supports better outcomes for all patients and we seek diversity in all aspects of our business.

Our Biopharma Success

At Bristol Myers Squibb, we uniquely combine the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers' needs, giving maximum priority to accelerating pipeline development, delivering sales growth, and continuing to manage costs. In recent years, we have outperformed most mega pharma companies, diversified companies, and pure biotech companies, having delivered 10 new medicines since 2019, and have a growing registrational portfolio. We are a BioPharma leader with a commitment to patients with serious disease, focused on finding innovative medicines to address unmet medical needs. Having transformed Bristol Myers Squibb into a benchmark BioPharma company, we now stand on the frontier of new possibilities with a commitment to making a meaningful difference in the lives of our patients. Continuous innovation is critical to our BioPharma strategy and is enhanced by our diverse workforce and inclusive culture. Over the years, Bristol Myers Squibb and its employees have received numerous distinguished awards and recognitions. Furthermore, we have the honor of continuing a legacy as one of the 100 Best Corporate Citizens, maintaining a perfect score on the Corporate Equality Index, and having been recently named one of the World's Most Admired Companies.





Bristol Myers Squibb focuses on discovering and developing innovative medicines that address serious diseases in areas of significant unmet medical need. We concentrate our research efforts in the following core therapeutic areas: Oncology, Hematology, Immunology, Cardiovascular, and Neuroscience.

150+ PROJECTS IN CLINICAL DEVELOPMENT



PATIENTS REACHED THROUGH ACCESS & EDUCATION PROGRAMS

9.3B

IN RESEARCH & DEVELOPEMENT SPEND

50+ INVESTIGATIONAL THERAPIES

SEE OUR FULL PIPELINE HERE

Cutting edge technologies & discovery platforms

Cell & gene therapy Protein homeostasis Biologics Small molecules Chemistry

Therapeutic areas with unmet needs

Oncology Hematology Cardiovascular Immunology Fibrotic diseases Neuroscience



Page 5 | 2025-2026 Fellowship Program

CARDIOVASCULAR

eliquis. (apixaban) tablets 525%



CELL THERAPY





lidecabtagene vicleucel)

🖑 Bristol Myers Squibb

HEMATOLOGY











BMS Fellowship, Primary Campus Location

Princeton Pike (PPK)

Lawrenceville, NJ

Page 6 | 2025-2026 Fellowship Program | 🖑 Bristol Myers Squibb

A Bristol Myers Spill



Post-Doctoral Program Governance

Executive Steering Committee



Melissa Harris, PharmD Senior Vice President, Regional Clinical Operations

Executive Sponsor



Priya Darouian, PharmD Head, Advanced Practice Programs & Medical Innovation

Steering Committee Lead



Thomas Lehman, PharmD Executive Director, WW Medical, Rheumatology

Steering Committee Co-Lead

Steering Committee Members



Cathy Merrill, PharmD Director, Clinical trial Lead, Medical Evidence Generation



Matt Lupo, MCIS Executive Director, US Commercial Regulatory Affairs

•



Ijeoma Oyetunde, PharmD Director, WW Medical Oncology Product Design and Delivery Lead



Jully Kim, PharmD Director, Global Congress Excellence, Congress Operations



Victoria Berger, PharmD Senior Clinical Scientist, Immunology & Fibrosis Clinical Develpoment

Peter Directo and Ar

Peter Fendt, PharmD Director, Business Insights and Analytics



Kim Tran, PharmD Vice President, US Field Medical Hematology-Oncology

Second-Year Co-Chief Fellows





Victoria Woo, PharmD

Second-Year Fellow BIA: US Cell Therapy Market Research

Ashley Volpe, PharmD, MHS, RPh

Second-Year Fellow Global Regulatory Strategy

(III) Bristol Myers Squibb™

2025-2026

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM



Page 9 | 2025-2026 Fellowship Program | 🖑 Bristol Myers Squibb

(III) Bristol Myers Squibb™

COMMERCIAL

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM



Page 10 | 2025-2026 Fellowship Program | 🖑 Bristol Myers Squibb

Sommercial Business Insights & Analytics



Victoria Woo, PharmD

Second-Year Fellow Rutgers University Ernest Mario School of Pharmacy



Sana Mansuri, PharmD

First-Year Fellow Rutgers University Ernest Mario School of Pharmacy At BMS, the Commercial Business Insights & Analytics (BI&A) division fuels bold decisions to create a competitive advantage and accelerate growth. This joint two-year fellowship is a unique opportunity for a Fellow to identify insights and work in a team to translate these findings into actionable recommendations for senior management. The Fellow will lead critical projects on cross-functional teams with stakeholders from Marketing, Market Research, Forecasting, Access, Medical Affairs, Business Development, and R&D Clinical Development.

The Fellow will spend the first year in Commercialization Competitive Intelligence and the second year in Market Research. While on both teams, the Fellow will synthesize data from both primary and secondary sources to develop actionable recommendations for business stakeholders. These rotational opportunities will allow the Fellow to help provide strategic partnerships and understand procedures within the BI&A organization.

COMPETITIVE INTELLIGENCE

- Monitor and assess the competitive environment, market trends, and emerging scientific data to inform clinical, medical, and commercial strategies
- Provide real-time context and implications of key market events to stakeholders and broader crossfunctional teams to catalyze discussion and potential strategic responses
- Plan and execute coverage of congresses to provide insights on key business questions that support brand or therapeutic area goals
- Communicate regularly with key stakeholders to identify gaps in knowledge and develop solutions to support business-critical activities

MARKET RESEARCH

- Work closely with cross-functional teams in Marketing, Medical, Sales, Forecasting, and Access to understand business needs and design various market research projects that address key business questions, with the opportunity to gain exposure to forecasting and analytics
- Manage and analyze primary research projects with vendor partners to effectively communicate insightful reports and presentations to guide brand strategies
- Maintain knowledge across the market and competitive trends to adapt to the dynamic customer environment
- Create, synthesize, and develop new market research techniques, solutions, and methods


The Fellow will develop valuable skills and experiences in identifying and prioritizing business opportunities and gaps. The Fellow will also develop transferable skills, including project management, vendor management, and enhanced presentation skills





Amie Lette, PharmD, MS

Second-Year Fellow University of Maryland School of Pharmacy



Lauren Hunter, PharmD, MBA

First-Year Fellow Butler University College of Pharmacy & Health Sciences This two-year fellowship offers the opportunity to join a rapidly-evolving access organization that leads in the industry to ensure patient and provider access to therapy. Within the fellowship program, the Fellow will have the opportunity to gain experience working in multiple components of the organization, with an emphasis in Hematology and Oncology. Through three rotational opportunities, the Fellow will build core foundational marketing skills, develop a comprehensive understanding of drug pricing, payer-provider reimbursement, and patient affordability. Additionally, the Fellow will gain exposure to many unique experiences and gain valuable insight into tactics and cross-matrix initiatives used to ensure patient access to quality care.

The fellowship is structured in flexible rotations within the core US market access teams which includes Patient Access Support Services, Pricing & Contracting, and Access Strategy. During this program, the Fellow will:

PATIENT ACCESS SUPPORT SERVICES

- Evaluate the evolving healthcare landscape to assess the implications for provider reimbursement and patient affordability
- Create materials, including both traditional and digital content, to communicate the proper billing and coding for infusible products to support launch and label updates

PRICING & CONTRACTING

- Understand challenges and business drivers across multiple channels including Payers, Integrated Delivery Networks, Group Purchasing Organizations, and Pathway organizations
- Gain experience in economic modeling to shape pricing strategy for new and existing products based upon shifting marketplace pressures and dynamics

ACCESS STRATEGY

- Contribute to the brand payer strategy by evaluating payer management trends, emerging access influencers, and the evolving competitive landscape
- Interact with medical strategy, health economics and outcomes research, and market research to develop promotional materials that communicate the value of our products to managed care organizations

ADDITIONAL EXPERIENCES

- Engage in field rides with external stakeholders alongside Access Reimbursement Managers, Health Systems Liaisons, and Account Executives
- Participate in potential opportunities with US market access matrix teams such as US Federal Policy, US Oncology Brand Marketing, and Global Market Access

US & WW CAR-T Marketing and Commercial

This newly created two-year commercial fellowship provides a unique opportunity to work in a fast-paced environment, emulating the speed of a biotech while existing in the structured lattice of a large pharma company. The Fellow will be involved in efforts that shape product strategies, drive the US CAR-T business, and identify commercialization opportunities on clinical stage and in-line CAR-T products.

The Fellow will spend their first year as a member of the US CAR-T marketing team collaborating with the matrix and external partners to ensure successful and timely execution of the brand strategy. Their second year will be spent in the WW Commercial CAR-T organization identifying market opportunities and developing commercial strategies that maximize US entry for future launches. The individual selected for this fellowship will have the chance to leverage their clinical background as they deliver on marketing strategies and assess the commercial opportunities of future CAR-T products.

During this program, the Fellow will:

US CAR-T MARKETING

- Drive execution of the Health Care Provider (HCP) tactical plan
- Navigate internal review processes to ensure timely and accurate preparation of tactical projects
- Manage agency/vendor partners to develop promotional materials and tactics
- Contribute tactical and strategic recommendations based on key internal and external medical and clinical updates from congresses, publications, etc
- Interact with customer-facing teams to mine customer insights, leading to the development of professional promotional strategy and materials

WW CAR-T COMMERCIAL

- Identify key value drivers and develop target product profiles based on understanding of current and potential market future trends
- Collaborate with key matrix team members to deliver robust market opportunity assessments that include a comprehensive review of the external competitive environment, external insights gathered from market research and discussions, market access considerations and revenue projections



(III) Bristol Myers Squibb™

CLINICAL DEVELOPMENT

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM



Page 14 | 2025-2026 Fellowship Program | 🖑 Bristol Myers Squibb

Global Drug Development



Victoria MacLelland, PharmD Second-Year Fellow University of Saint Joseph, School of Pharmacy and Physician Assistant Studies



Yasmin Pirestani, PharmD, RPh Second-Year Fellow Thomas Jefferson University



Leah White, PharmD First-Year Fellow UNC Eshelman School of Pharmacy



Mirna Kalayjian, PharmD First-Year Fellow University of California, San Francisco School of Pharmacy

The Global Drug Development (GDD) organization is responsible for developing new medicines for the treatment of various diseases worldwide. Fellows within GDD function as Associate Clinical Scientists (CS) and would focus on the science and strategy of drug development. The Fellows will learn various aspects of global clinical studies (Phases I-III) including study initiation, maintenance, and closure activities.

GLOBAL DRUG DEVELOPMENT FELLOWSHIP OBJECTIVES:

- Understand the key foundations of clinical trial development and how they relate to the overall drug development process (i.e. study design, selecting study endpoints, randomization/stratification, control, blinding, selection of population, and study assessments).
- Become a proficient CS and effective cross-functional study team contributor throughout the clinical trial process by learning to develop study protocols and protocol amendments, informed consent forms, patient narratives, clinical study reports (CSR), Investigator Brochures (IB), Investigational New Drug (IND) safety updates, Development Safety Update Report (DSUR), and other regulatory submission documents.
- Work closely with the CSs, CTPs (Clinical Trial Physician) and study team in making study-specific recommendations, providing clinical research expertise, presenting protocol specific topics, responding to health authority requests, and supporting the team at various therapeutic area conferences.
- Support the study team in comprehensive clinical data review and analysis via available data review tools such as patient profiles, data review reports, and data listings.
- Partner with Clinical Operations, Data Management, Statistics, Drug Safety, Regulatory, Clinical Pharmacology, Medical and Commercial teams to support the scientific aspects of clinical development.

The Global Drug Development fellowship is a 2-year program primarily focused on developing new therapies in solid tumor oncology, hematology, cellular therapy, cardiovascular & neuroscience and immunology, where there exists large unmet needs. This year, one Fellow will be recruited to support programs within the Hematology therapeutic area. Bristol Myers Squibb is at the forefront of drug research with an extensive and quickly developing pipeline. This fellowship opportunity will allow the Fellow to work on novel and innovative therapies that address the unmet medical needs of patients with serious diseases.

(III) Bristol Myers Squibb™

MEDICAL

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM



Page 16 | 2025-2026 Fellowship Program | 🖑 Bristol Myers Squibb

WW Oncology Medical Education & US Oncology Pan Tumor Medical Strategy



Sam Pike, PharmD, RPh

Second-Year Fellow University of Michigan College of Pharmacy



Sirisha Neti, PharmD


First-Year Fellow Rutgers University Ernest Mario School of Pharmacy This two-year fellowship offers a comprehensive and integrated approach to learning and aligning oncology medical strategy across our medical organization. The Fellow will support medical teams in developing strategies for both marketed products and pipeline assets, executing activities for successful product launches, contributing to healthcare provider (HCP) education, and ensuring the safe and appropriate use of our medicines by HCPs. The fellowship includes rotational experiences in two key areas of our medical organization: an 8-month rotation in Worldwide Oncology Medical Education, followed by a 15-month rotation in US Oncology Pan Tumor Medical Strategy.

MEDICAL EDUCATION

- Understand what Independent Medical Education (IME) is and the role it plays in the organization
- Understand IME medical strategy and functional plan
- Develop proficiency in medical education grant proposal review, know what a robust grant consists of, and understand the learning science of Adult Learning Principles
- Author a request for education (RFE) and lead it through the execution process from start to finish
- Evaluate BMS-supported medical education activities assessing for medical accuracy, fair-balance, and alignment to approved grant proposals
- Analyze outcomes data from BMS-supported medical education activities. Communicate behavioral changes, competence/knowledge gains, learner questions and remaining education gaps to the medical matrix teams
- Interface with medical education communication companies to understand provider capabilities and assess outcomes of activities
- Work with the publications and medical content teams to gain exposure and experience in both areas

PAN TUMOR MEDICAL STRATEGY

- Engage in medical strategy tactics, including thought leader interactions, advisory board discussions, gathering field medical insights, and aligning with oncology medical partners on safety/ patient management, administration, and other pan tumor topics
- Lead the strategic communication, collaboration, and awareness of pan tumor efforts while partnering on execution with functional teams including US and Worldwide Medical, Clinical Development, Commercial, and Field Medical
- Participate in the development and execution of pan tumor deliverables, including proactive patient management resources, medical proactive/reactive resources, and training materials for matrix colleagues



US Cardiovascular Medical Strategy & Field Medical Sciences



Tia Belvin, PharmD

Second-Year Fellow University of North Carolina Eshelman School of Pharmacy



Mike Zatkos, PharmD, RPh

First-Year Fellow University of Pittsburgh School of Pharmacy This two-year fellowship provides a unique opportunity to develop expertise in strategic in-house medical affairs and field medical activities. The Fellow will acquire cardiovascular disease state knowledge and master the BMS cardiovascular product portfolio. Additionally, the Fellow will work on high priority projects and initiatives aligned with the Medical Plan to support impactful HCP interactions. The Fellow will develop leadership and communication skills through collaboration across the US Medical matrix teams and other key partners. Key activities and learnings will include:

MEDICAL STRATEGY

- Participate in the US Medical matrix team to support strategic planning based on the unmet medical needs from the perspectives of patients, providers, and payers
- Support the execution of the Medical Strategy tactical plan by working across matrix teams (Marketing, Field Medical, Independent Medical Education, Advocacy, Clinical Development, Legal and Regulatory) as well as with alliance partners
- Collaborate with cross-functional medical team members to deliver on key medical initiatives, including advisory boards, proactive messaging, reactive medical communication, and publication strategy
- Support development of medical training materials for sales representatives and deliver medical presentations at sales training sessions
- Contribute towards congress strategy and lead the execution of National Congress planning activities as part of the CV Medical Plan

FIELD MEDICAL SCIENCES

- Complete MSL trainings and certification processes for the entire CV profile
- Engage thought leaders in scientific discussions during field-based activities with CV MSLs
- Assess/identify gaps in MSL resources and collaborate with medical strategy on the development of MSL scientific resources and trainings
- Collaborate with the Field Medical Leadership Team to support development and implementation of field medical priorities
- Contribute to scientific congress Field Medical initiatives and planning
- Develop an understanding of clinical trial site maintenance and the MSL educational role

Ull Bristol Myers Squibb

US & WW Immunology Medical Strategy



Somto Egbuonu, PharmD

Second-Year Fellow Texas Tech University Health Sciences Center



Alex Kayal, PharmD

First-Year Fellow Rutgers University Ernest Mario School of Pharmacy This two-year fellowship provides a unique opportunity to work in two of the most exciting and competitive areas of immunology research and pharmaceutical development today: Dermatology and Rheumatology. Individuals participating in this fellowship will gain a broad understanding of Medical Affairs through both participatory and leadership experiences from the perspective of both the US and Worldwide Medical Strategy Teams. During the fellowship, the Fellow is expected to experience several important market events including post-launch support in dermatology and several phase 2/phase 3 study read outs. Graduates of this fellowship have gone on to lead successful careers in various aspects of Medical Affairs including Medical Strategy, Scientific Communications, Clinical Development, Medical Science Liaison, Medical Information, and Independent Medical Education.

US MEDICAL STRATEGY - DERMATOLOGY & RHEUMATOLOGY

- Participate in strategic planning with the US Medical Matrix Team based on unmet medical needs from the perspectives of patients, providers, and payers
- Lead medical projects in partnership with the broader medical matrix team members (Field Medical, Medical Communications, Independent Medical Education, Sales, Marketing, Outcomes Research, Promotional Review Team, Legal, and Global Pharmacovigilance & Epidemiology)
- Lead and participate in key aspects of medical affairs including data generation, content development, training, insight reporting, advisory boards, and congress planning
- Conduct medical review of promotional and non-promotional materials in collaboration with Legal, Regulatory, and Marketing teams

WORLDWIDE MEDICAL STRATEGY - RHEUMATOLOGY

- Lead development and execution of the Global Medical Plan in partnership with key international market teams (eg, US, EU, Asia-Pacific), Clinical Development, & Commercial
- Prepare for a commercial launch and several Phase 2/3 data releases for deucravacitinib (a selective TYK2 inhibitor) in Rheumatology
- Engage International Key Opinion Leaders via advisory boards, steering committees, and international conferences to inform and elevate BMS strategy
- Identify educational needs among Rheumatologists and Dermatologists and execute plans to fulfill them; eg, disease education, pathway materials, conference symposia, review articles
- Develop integrated data generation plans and review/approve investigator sponsored research proposals to inform appropriate use of BMS medicines and fulfill unmet medical need

WW & US Oncology Medical Strategy



Caitlin Henley, PharmD Second-Year Fellow

Second-Year Fellow Thomas Jefferson University



Sharmaine Cubelo, PharmD

First-Year Fellow Temple University School Medical Strategy is where scientific and clinical knowledge meet strategic application. This two-year fellowship provides a unique opportunity to support the development and execution of Worldwide and US Oncology Medical Strategy and other medical activities. During the first year in Worldwide Medical Oncology, the Fellow will focus on developing the global strategy for new indications in a wide array of tumor types through collaborative efforts with BMS regional offices around the world. During the second year in US Medical Oncology, the Fellow will focus on developing and executing the US strategy for the successful launch and continued support of a wide range of indications through medical engagements, conferences, and launches. Throughout these 2 years, the Fellow will gain exposure to various stakeholders and develop leadership skills by supporting and leading medical initiatives in collaboration, Regulatory, Publications and Scientific Content, Field Medical, Commercial, HEOR, Competitive Intelligence, Access and more). Additionally, the Fellow will have opportunities to collaborate closely with the patient advocacy team. This includes partnering to present and execute patient advocacy advisory boards, attending patient advocacy meetings at congresses, and developing various patient-related tactics. This will provide the Fellow with a deep understanding of how our work directly impacts patients' lives.

WORLDWIDE MEDICAL STRATEGY

- Gain experience in the development of a strategically-aligned Global Medical Plan based upon unmet medical need by collaborating with a cross functional, multi-regional (i.e., US, EU, Asia-Pacific) Worldwide Medical matrix team
- Engage with external Thought Leaders in an effort to exchange and gather scientific and clinical knowledge through investigator meetings, advisory boards, Thought Leader Engagements (TLEs), publication planning, and congresses
- Lead the execution of medical deliverables that are closely aligned with the strategic Global Medical Plan, including National and International Congress planning for activities such as advisory boards, symposia, and TLEs
- Collaborate with BMS country-specific medical colleagues to collect field insights that will support strategic planning and tactical execution
- Actively participate in the review and approval process of Investigator Sponsored Research proposals that are aligned with the data generation plan detailed in the Global Medical Plan

US MEDICAL STRATEGY

- Participate in key medical activities such as medical advisory boards, Field Medical resources and trainings, Congress planning (e.g., ASCO, ASCO GI), reactive content, and the communication strategy, including publications
- Collaborate with US Medical matrix teams (e.g., Field Medical, Evidence Generation, Patient Advocacy, Medical Education, and Congress Management) to support planning and delivery of medical objectives based on unmet medical needs
- Collaborate and communicate with US Commercialization & Access organizations to integrate medical perspectives into the commercialization process and ensure appropriate alignment between commercial and medical plans
- Engage with external thought leaders and scientific experts to assess unmet medical needs to develop appropriate medical strategies



WW Cardiovascular Medical Affairs



Elaine Marji, PharmD

First-Year Fellow University at Buffalo School of Pharmacy and Pharmaceutical Sciences This two-year fellowship provides an opportunity to work across the Medical Affairs function within the Cardiovascular WW Medical organization, where the Fellow will learn how to communicate key clinical and real-world evidence data across various channels to inform healthcare decision-making. Within this role, the Fellow will gain experience in the generation of strategic and prioritized scientific publications, content, and medical education for HCPs and patients. While doing so, the Fellow will become adept in the planning and execution of scientific communication deliverables including, but not limited to, journal publications, congress presentations, reactive and proactive slide decks, standard response documents, and dossiers. The Fellow will be afforded a rotational opportunity of up to 6 months to engage in developing and executing strategic initiatives including advisory boards, identifying educational needs, and data generation plans, to gain an understanding of Medical Affairs. This position encourages the cultivation of critical thinking and leadership skills through cross-functional collaboration with various internal and external stakeholders (e.g., Medical Strategy, Health Economics and Outcomes Research [HEOR], Field Medical, Field HEOR, Medical Information, Clinical Development, Regulatory, and third-party vendors). Key activities and learnings will include:

SCIENTIFIC PUBLICATIONS

- Gain experience through collaboration with WW and US Medical Strategy, HEOR, and other stakeholders in developing strategic and impactful clinical and HEOR publications for BMS assets
- In collaboration with WW & US Medical Strategy, external authors, and appropriate internal stakeholders, develop
 publications adhering to BMS publication standards including abstracts, congress presentations, and manuscripts
 focused on disease burden, unmet medical needs, and the clinical and economic value of BMS assets
- Lead the execution of publication plans and develop skills for managing stakeholders, both external and internal, in multiple functional areas to ensure strategic alignment of the publication plans

WW AND US SCIENTIFIC CONTENT

- Understand the unique information needs of HCPs and patients to ensure strategic and prioritized information delivery
- Collaborate with WW & US Medical Strategy, HEOR, medical field teams, and other stakeholders to ensure development of fair-balanced scientific content with the highest degree of medical integrity, accuracy, and clinical relevance
- Lead content creation of medical communication deliverables involving clinical studies, economic analyses, and
 real-world evidence pertaining to BMS medicines. Deliverables include AMCP dossiers, Medicaid submissions,
 submissions to guideline bodies, reactive slide decks, standard response documents, FAQ documents for
 medical field teams, and responses to medical information inquiries

MEDICAL EDUCATION

- Evaluate BMS-supported medical education activities assessing for medical accuracy, fair balance, and alignment to approve grant proposals
- Analyze outcomes data from BMS-supported medical education activities and develop infographics to report on metrics from IME events such as demographic reach, target audience, downloads, and impact on clinician learners
- Interface with medical education communication companies to understand provider capabilities and assess outcomes of activities

WW MEDICAL STRATEGY

- Participate in the Medical Matrix Team to support strategic planning based on the unmet medical needs and knowledge gaps from the perspectives of patients, providers, and payers
- Collaborate with cross-functional medical team members to deliver on key medical initiatives including advisory boards, proactive messaging, reactive medical communication, and publication strategy

Page 21 | 2025-2026 Fellowship Program | 🖑 Bristol Myers Squibb

WW Immunology and Neuroscience Medical Communications and Medical Strategy



Raazi Siddiqui, PharmD

Second-Year Fellow Saint Joseph's University, Philadelphia College of Pharmacy This two-year fellowship provides an opportunity to work across the Medical Communications and Medical Strategy functions within the Worldwide Medical organization. The Fellow will learn how to communicate key clinical and economic data across various channels to inform healthcare decision-making. Within this role, the Fellow will gain experience in the generation of strategic and prioritized scientific publications, content, and medical education for HCPs and patients. While doing so, the Fellow will become adept in the planning and execution of scientific communication deliverables, including but not limited to, journal publications, congress presentations, reactive slide decks, FAQ, standard response documents, and dossiers. In the second year, the Fellow will gain a broader understanding of Medical Affairs through participation and leadership in experiences from the perspective of the Worldwide Medical Strategy team. The fellow will engage in developing and executing strategic initiatives including advisory boards, identifying educational needs, and data generation plans to ensure alignment with the immunology strategic imperative. This position encourages the cultivation of critical thinking and leadership skills through cross-functional collaboration with various internal and external stakeholders (e.g., Medical Strategy, Medical Information, Health Economics and Outcomes Research (HEOR), Field Medical, Clinical Development, Clinical Science, Field HEOR, Legal and third-party vendors). Key activities and learnings will include:

MEDICAL COMMUNICATIONS

- Understand the unique information needs of healthcare professionals, payers, access influencers, and patients to ensure strategic and prioritized information delivery
- Collaborate with WW & US Medical Strategy, HEOR, medical field teams, and other stakeholders to ensure development of fair-balanced scientific content with the highest degree of medical integrity, accuracy, and clinical relevance
- Lead content creation of medical communication deliverables involving clinical studies, economic analyses, and real-world evidence pertaining to BMS medicines. Deliverables include reactive slide decks, standard response documents, Q&A documents for medical field teams, and responses to medical information inquiries
- Gain experience through collaboration with WW and US Medical Strategy, HEOR, and other stakeholders in developing strategic and impactful clinical and HEOR publications for BMS assets
- In collaboration with WW & US Medical Strategy, external authors, and appropriate internal stakeholders, develop publications adhering to BMS publication standards including abstracts, congress presentations, and manuscripts focused on disease burden, unmet medical needs, and the clinical and economic value of BMS assets
- Lead the execution of publication plans and develop skills for managing stakeholders, both external and internal, in multiple functional areas to ensure strategic alignment of the publication plans

MEDICAL STRATEGY

- Participate in the Medical Matrix Team to support strategic planning based on the unmet medical needs from the perspectives of patients, providers, and payers
- Collaborate with cross-functional medical team members to deliver on key medical initiatives including advisory boards, proactive messaging, reactive medical communication, and publication strategy
- Review promotional and non-promotional materials alongside Legal, Regulatory, and Marketing teams
- Engage with external Thought Leaders to exchange and gather scientific and clinical knowledge through investigator meetings, advisory boards, Thought Leader Engagements (TLEs), publication planning, and congresses

US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG)



Karandeep Singh, PharmD

Second-Year Fellow St. John's University, College of Pharmacy and Health Sciences



Chris Higgins, PharmD Second-Year Fellow Thomas Jefferson University



Sydney Ross, PharmD First-Year Fellow University of Iowa College of Pharmacy

US Immunology and Neuroscience Field Medical & Medical Evidence Generation (MEG) position is a twoyear fellowship that will provide a unique opportunity to gain expertise in multiple dimensions of the medical affairs function in the immunology and neuroscience division. During their first year, the fellow will join the US Field Medical Immunology & Neuroscience team and participate in key projects, critical to the success of new product/indication launches and currently approved products. The fellow will gain an appreciation for core Field Medical competencies spanning field training, resource creation, operations, and thought leader (TL)/ investigator engagement. In their second year, the fellow will join the MEG team and contribute to the development and implementation of the Integrated Evidence Plan (IEP) and interact with the different modalities of evidence generation (investigator-sponsored studies, interventional and noninterventional company-sponsored trials, collaborative research, data mining and exploratory analysis among others). The fellow will function as an Associate Clinical Scientist (CS) focusing on the science and strategy of medical affairs-sponsored trials (MASTs), learning various aspects of clinical studies (Phase IIIb/IV) including study design, initiation, maintenance, and closure activities.

US FIELD MEDICAL

- Serve as an integral part of the I&N (Immunology and Neuroscience)Field Medical Strategy and Training team and key contributor for field medical planning, stakeholder communications, and launch/life-cycle management projects
- Gain product and therapeutic expertise in I&N as foundational knowledge to apply to various projects and activities
- Collaborate with home office and field matrix teams to assist in the development of training initiatives and medical resources
- Contribute on innovative tactics and/or platforms to elevate MSL development and productivity in the field
- Participate in MSL trainings, assessments, and interactions. Fellow will have the opportunity to accompany MSLs on field rides and virtual interactions to gain an understanding of diverse experiences with TLs and study investigators

MEDICAL EVIDENCE GENERATION (MEG)

- Support the development, tracking and maintenance of Integrated Evidence Plans (IEPs) that reflect asset strategy, market priorities and medical evidence generation support in partnership with the I&N Global Medical Disease Team and cross-functional teams including Global Drug Development (GDD), Translational Development, Health Economics and Outcomes Research (HEOR), and others
- Develop Areas of Interest (AOI) based on key open data questions (ODQ) identified in the IEP with market input in collaboration with the I&F Global Medical Disease Team
- Manage the scientific aspects of the ongoing I&N Investigator-sponsored Research (ISR) book of work and interface with all key stakeholders across the matrix
- Conduct regular book of work reviews in partnership with GDO (Global Development Operations) with key medical and development stakeholders, under their remit. Identify studies at risk for failing to meet timelines and negotiated mitigation plans with key internal stakeholders and investigators
- Assist in the reviews of concepts through RFP (Request For Proposals) process, as appropriate, including providing context for ongoing book of work, area of interest development, and upcoming data read-outs
- On MAST studies, the Fellow will work closely with the CTL (Clinical Trial Lead) and study team in making study-specific recommendations, providing clinical research expertise, presenting protocol specific topics, responding to health authority requests, and supporting the team at various therapeutic area conferences.
- Support the study team in comprehensive clinical data review and analysis via available data review tools such as patient profiles, data review reports and data listings.

Page 23 | 2025-2026 Fellowship Program | 🖑 Bristol Myers Squibb

JS & Worldwide Hematology Medical Affairs



Timothy Jurasik, PharmD First-Year Fellow Temple University School of Pharmacy The two-year Medical Affairs fellowship is designed to provide broad exposure and opportunities to understand the various roles within the Hematology Medical Affairs organization. Throughout the fellowship, the Fellow will further develop their knowledge base within the hematology space by acquiring disease state knowledge and mastering clinical data involving the Bristol Myers Squibb product portfolio and competitor data. The Fellow will learn various aspects of clinical research (company sponsored trials, investigator-initiated trials, cooperative group trials, and registries) while working collaboratively with medical disease teams and cross-functional partners.

US MEDICAL

- Gain a broad knowledge and understanding of assigned disease areas including, but not limited to: disease biology, currently available therapeutic options, agents in development, and unmet medical needs for specific patient segments
- Gain product-related expertise in each assigned disease area and engage in scientific and strategic discussions with key internal and external stakeholders
- Support the medical disease teams with content preparation and planning for medical congresses (e.g. ASCO, ASH) and other key external meetings, including advisory boards, scientific steering committee meetings, and thought leader engagements
- Collaborate with cross functional team members, including Medical Science Liaisons (MSLs), Scientific Communications, Scientific Education, Medical Information, and Learning & Development teams, to create and execute on medical tactical plans

WORLDWIDE MEDICAL

- Engage with international Key Opinion Leaders via congresses, advisory boards, symposiums
- Identify key data gaps in HCP education and lead execution of plans to educate and inform of BMS strategy
- Contribute to the evaluation of investigator-initiated trial concepts and how each concept strategically relates to open research questions that have been prioritized within the department and disease team



(III) Bristol Myers Squibb™

REGULATORY

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM



Page 25 | 2025-2026 Fellowship Program | 🖑 Bristol Myers Squibb

Global Regulatory Strategy



Ashley Volpe, PharmD, MHS, RPh

Second-Year Fellow Fairleigh Dickinson University School of Pharmacy and Health Sciences



Vaidehi Patel, PharmD,

MBA

First-Year Fellow Saint Josephs University, Philadelphia College of Pharmacy This two-year fellowship provides the opportunity to establish a broad understanding of Global Regulatory Strategy and its role in the drug development process. The Fellow will obtain direct experience and exposure to products at various stages of development and will learn important considerations for working with key regulatory agencies such as FDA and EMA. Optional rotation(s) to enhance the fellowship experience are offered based on Fellow interest and opportunities in other regulatory disciplines such as Precision Medicine, Commercial Regulatory Affairs, or Global Labeling. During this program, the Fellow will:

- Participate in the development of global regulatory strategies supporting development, approval, and maintenance of drugs and biologics
- Contribute to identification and assessment of regulatory risks and their mitigation
- Participate in planning and preparing for Health Authority (HA) interactions and assessing the impact of HA feedback on an asset's development plan
- Draft submission documents, including for INDs, NDA/BLAs, and expedited regulatory designation requests
- Conduct regulatory intelligence research to inform development program strategy and decision-making
- Manage responses to Health Authority queries
- Collaborate with matrix team members to identify solutions that meet regulatory requirements as well as commercial objectives
- Partner with Global Regulatory Policy team to evaluate evolving regulatory topics



US Commercial Regulatory Affairs: Advertising & Promotion



Gabriel Santos, PharmD

First-Year Fellow Rutgers University, Ernest Mario School of Pharmacy The US Commercial Regulatory Affairs group at Bristol Myers Squibb provides strategic regulatory guidance within the company on the Food and Drug Administration (FDA) advertising and promotion regulations to support good business practices. The regulatory advice is provided to the marketing organization to ensure the highest level of ethics and integrity in the promotion of Bristol Myers Squibb products. The group collaborates with a variety of functions including Marketing, Medical Affairs, Legal, Global Labeling, Managed Markets, Global Regulatory, Safety, and Biometrics. The Fellow will be assigned to a primary therapeutic area. Key activities and learnings will include:

- Gaining an understanding of and ensuring consistency between key federal regulations and Bristol Myers Squibb policies
- Analyzing the impact of FDA Office of Prescription Drug Promotion (OPDP) enforcement actions and assessing the regulatory implication to commercial activities
- Assisting in the regulatory review of proposed promotional materials and programs created by Marketing, Sales, or Corporate Affairs and submissions to OPDP
- Collaborating with matrix team members to advise on the development of marketing campaigns that meet regulatory requirements as well as commercial objectives



(III) Bristol Myers Squibb™

BMS RESIDENCY

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM



Page 28 | 2025-2026 Fellowship Program | 🖑 Bristol Myers Squibb

Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency



Minneh Oyas, PharmD, RPh PGY2 Resident University of Hawaii at Hilo

The Bristol Myers Squibb Foundation's (BMSF) approach to improving global health is empowering local health systems through strategic investments in capacity building and health systems strengthening initiatives, improving access to healthcare, and promoting health equity worldwide. The program offered through the Rutgers Institute for Pharmaceutical Industry Fellowship Program, entails the resident spending approximately six months in sub–Saharan Africa with the BMSF Global Cancer Disparities – Africa program team to build pharmacology capacity and transfer skills to partner organizations. Activities may include:

- Training of pharmacy and other healthcare professionals in disease state management and pharmacotherapy
- Developing protocols and proposals incorporating the management of cancer in low to middle-income countries (LMICs)
- Assisting countries develop cancer surveillance programs and registries to collect data and develop treatment recommendations
- Exposure to project implementation and management on field sites
- Engaging community members and organizations through outreach to help improve health outcomes

The Resident will then complete the remainder of the program in Lawrence Township, New Jersey, and Manhattan, New York City developing a grant management and operations skill set through the U.S. Health Disparities in Neuropsychiatry portfolio and/or other BMSF initiatives (including our Global Cancer Disparities – U.S./Brazil/India portfolios and the Robert A Winn Diversity in Clinical Trials Award Program) that address healthcare inequities. Activities may include:

- Supporting grant management activities to gain greater insight into health philanthropy within the pharmaceutical industry setting
- Researching issues for the development of grant program strategies
- Providing expert review and technical assistance for pharmacy-related issues
- Connecting project goals with policy and advocacy advancement
- Reviewing grantee reports and learning responsibilities as a grantmaker

As a Rutgers adjunct faculty through the Rutgers Institute for Pharmaceutical Industry Fellowship Program, there will be opportunities for the Resident to enhance their experience by collaborating with faculty through scholarship, publication, teaching and maintenance of clinical skills.

APPLICATION REQUIREMENTS:

Applicants can pre-schedule an interview at the ASHP Midyear Clinical Meeting through the Personnel Placement Service (PPS). Requirements include: PharmD from an ACPE-accredited institution, Completion of a PGY-1 residency or equivalent experience is strongly preferred, Curriculum vitae, Three letters of recommendation, Letter of intent addressing your interest in global/public health and long-term plans, and Candidates must be willing and able to relocate to sub–Saharan Africa for 6 months.

Page 29 | 2025-2026 Fellowship Program | 🖑 Bristol Myers Squibb







POLICY & PATIENT ADVOCACY

Alexis Glenn, PharmD

First-Year Fellow University of Maryland School of Pharmacy



US ONCOLOGY MARKETING

Muhammad Usman, PharmD

First-Year Fellow St. John's University College of Pharmacy and Health Sciences

US ONCOLOGY AND HEMATOLOGY MEDICAL SCIENCE LIAISON & FIELD MEDICAL STRATEGY AND OPERATIONS



Joanne Lu, PharmD

Second-Year Fellow University of Maryland School of Pharmacy



Ryan Kendra, PharmD

First-Year Fellow Binghamton University School of Pharmacy and Pharmaceutical Sciences



Leadership Spotlight



Melissa Harris, PharmD

Executive Sponsor Senior Vice President, Regional Clinical Operations Fellowship Year 2001-2002

Bristol Myers Squibb is a great company for pharmacists who are wanting to enter the pharmaceutical industry. The company recognizes the value of the unique skill set, training, and experience that enables pharmacists to excel and rise to important management and leadership roles. The diversity and cohesiveness of our PharmD program, and our associated pharmacy community at Bristol Myers Squibb, provides an exceptional experience of seeing, doing, and teaching, which readily prepares our Fellows/Residents to become future leaders within both our Medical and Commercial organizations. As leaders at Bristol Myers Squibb, we appreciate the importance of attracting and retaining these talented individuals to fulfill the Bristol Myers Squibb Company mission of helping patients prevail over serious diseases. The Rutgers PharmD Fellowship Program is clearly an important part of our talent acquisition strategy and is key to building and cultivating an innovative and diverse workforce at Bristol Myers Squibb.



Priya Darouian, PharmD

Steering Committee Lead Head, Advanced Practice Programs & Medical Innovation Fellowship Year 2003-2004

The Bristol Myers Squibb fellowship program has provided me with a solid foundation that prepared me for a successful career in the pharmaceutical industry. As a Fellow, I was an integral part of my team and was provided with a breadth of experiences. My preceptors and mentors were truly invested in my career growth and development. The experiences and friendships I have gained throughout my fellowship and current role are invaluable and will last me a lifetime. The program provides you with the necessary tools and opportunities you need to lead you on a path towards a rewarding career. I am proud to be a part of an organization that has a commitment and passion for patients.



Thomas Lehman, PharmD

Co-Steering Committee Lead Executive Director, WW Medical, Rheumatology Fellowship Year 2012-2014

Selecting a fellowship at BMS was one of the best decisions I made to jump start my career during the fellowship interview and selection process. As a company with both a people and patient centric culture, a career at BMS for me has meant some of my proudest moments have had an impact for both patients and my career. Over a decade later I look back on my time and think about the people both in the fellowship community and beyond who have helped me succeed and contributed to my professional development. I can recommend no better place to both start and grow your career.



Bristol Myers Squibb Fellowship Alumni

Medical

Adesumbo Odunlami Senior Manager, Global Health Equity Platform Alejandro Nava Consultant, US Medical Scientist, Oncology Anthony Salvatore Senior Director, US Medical, Oncology Antonia Christodoulou Associate Director, Worldwide Medical, Rheumatology Austin Bock Associate Director, Worldwide Medical/Medical Communications, Immunology & Neuroscience Brandon Elpers Director, Worldwide Medical, Lung Fibrosis Carmelo Alonso Associate Director, Medical Scientist, US Medical Oncology Catherine Merrill Director, Clinical Trial Lead, Oncology Corey Rantz Associate Director, Medical Scientist, Oncology Divya Patel Associate Director, US Medical Scientist, Oncology Dorothy Zissler Associate Director, Worldwide Medical Affairs, Myeloid Franco Dickson Associate Director, Worldwide Medical/Medical Communications, Oncology ljeoma Oyetunde Director, Worldwide Medical, Oncology Jaime Bunn Director, Worldwide Medical/Medical Communications, Cardiovascular Jagruti Amin Associate Director, US Medical Promotional Review, Oncology Joseph Kosto Associate Director, Franchise Medical Services Josh Linton Director, US Medical, Oncology Jully Kim Director, Global Congress Excellence Kaleen Barbary Director, Worldwide Medical, Oncology Keith Wittstock Director, US Medical Scientist, Gastroenterology Max Prokopovich Associate Director, Medical Scientist, Oncology Micah Anthony Associate Director, Worldwide Medical, Immunology & Neuroscience Medical Communications Nabomita Thomas Senior Director, US Medical, Oncology Patrick Liu Associate Director, US Myeloid Medical Excellence and Engagement Lead Pavit Singh Senior Director, US Medical Affairs, Hematology Priya Darouian Head, Advanced Practice Programs & Medical Innovation Ruchi Shah Senior Manager, Medical Scientist, Oncology Samantha Pomponi Director, Worldwide Medical, Rheumatology Sonie Lama Executive Director, Cardiovascular, US Medical Lead Sruthi Gaddam Director, Worldwide Medical, Oncology Stella Han Senior Medical Director, Worldwide Medical, Cardiovascular Swara Kasbekar Associate Director, US Medical Oncology Thomas Lehman Executive Director, Worldwide Medical, Rheumatology Trixia Camacho Vice President, Head of Global Clinical Research Collaborations, Medical Evidence Generation

Vincent Tran Associate Director, Medical Promotional Review, Hematology

Field Medical

Asia Ridley Medical Science Liaison, Oncology Bryandt Douglas Medical Science Liaison, Cell Therapy Daniel Dilanji Senior Medical Science Liaison, Neurology Gabriela Sikorska Medical Science Liaison, Dermatology Justin Balint Director, US Field Medical Strategy, Hematology – Oncology Karan Verma Senior Medical Science Liaison, Neurology Katherine Sprague Director, US Field Medical Portfolio Engagement Strategy, Cardiovascular Khushbu Shah Associate Director, US Field Medical Strategy, Hematology Kim Tran Vice President, US Field Medical, Hematology - Oncology Lauren Marbury Senior Medical Science Liaison, Dermatology Marie Labib Medical Science Liaison, Hematology Rachel Goldberg Medical Science Liaison, Immunology Raena Rhone Medical Science Liaison, Neurology Teena John Medical Science Liaison, Neurology Zack Inge Senior Medical Science Liaison, Cardiovascular

BMS Foundation (Corporate Philanthropy)

Mason Chiang Associate Director, BMS Foundation Ornesha Watson Associate Director, BMS Foundation

Commercial

Bernard Lee Director, US Commercialization Analytics, Immunology Chloe Thomas District Business Manager, Oncology Christine Ghobrial Director, Worldwide Commercial, Oncology Christy Wong Senior Product Manager, US Marketing, Cell Therapy Dylan Atkinson Associate Director, US Marketing, Lung Enoch Yue Associate Director, Worldwide Commercialization, Cardiovascular Evelyn Abramson Associate Director, US Marketing, Gl Oncology Frances Sousonis Associate Director, US Marketing, Thoracic Oncology Jade Hoang Director, US Eliquis Strategy, Operations and Commercial Model Jake Kinley Senior Manager, US Marketing, Oncology Karishma Parekh Senior Manager, HCP Professional Education, Reblozyl Marketing Kevin Kao Senior Product Manager, Marketing, Thoracic Oncology Lindsey Prima Director, Worldwide Commercial Strategy, Oncology Nina Johnson Associate Director, US Marketing, Melanoma Peter Fendt Director, Customer & Market Insights, Hematology/CAR-T Spencer Heath Director, Worldwide Commercial, Early Assets, BD and Strategy

Market Access & Pricing

Emily O'Neill Associate Director, US Strategic Payer Marketing, Cardiovascular Jennifer Liu Associate Director, US Access Marketing, Melanoma Josh Dadural Senior Product Manager, Access Strategy, Oncology Prianka Singh Director, Global Pricing and Access Strategic Lead

Regulatory Affairs

Alexander Cheung Associate Director, US Commercial Regulatory Affairs Amandeep Riar Associate Director, Global Regulatory Strategy, Hematology Christine Alonso Senior Director, US Commercial Regulatory Affairs, Oncology Elsa Pan Senior Director, US Commercial Regulatory Affairs, Immunology/CV/Mature Brands Jessica Zhu Senior Manager, Global Regulatory Strategy, Oncology Kiri Roland Associate Director, Advertising and Promotion Commercial Regulatory Affairs, Oncology Robert Kalesnik-Orszulak Senior Director, Global Regulatory Strategy, Oncology Sekayi Mushonga Vice President, Global Regulatory Strategy, Immunology Sohrab Sadeghi Senior Manager, Global Regulatory Strategy, Hematology Trushna Shah Director, Regulatory Affairs, Immunology & Neuroscience Yen Krystal Miao Associate Director, US Commercial Regulatory Affairs

Clinical

Amy Kim Associate Director, Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology
Andrew Mettias Senior Manager Clinical Scientist, Late Clinical Global Drug Development, Oncology
Brenda Yuan Associate Directo, r Senior Clinical Scientist, Cell Therapy
Brielle Carramusa Senior Manager, Clinical Scientist, Cardiovascular & Neuroscience
Corey Ritchings Clinical Development Lead, Oncology
Lana Mudarris Senior Manager, Clinical Scientist, Cardiovascular & Neuroscience
Maha Elgohail Associate Director, Senior Clinical Scientist, Cardiovascular & Neuroscience
Melissa Harris Senior Vice President, Regional Clinical Operations
Nicholas Favatella Director, Lead Clinical Scientist, Oardiovascular & Neuroscience
Nishanth Viswanath Senior Manager, Clinical Scientist, Oncology
Shannon Chandy Clinical Trial Lead, External Clinical Collaborations, Oncology
Victoria Berger Associate Director, Senior Clinical Scientist, Immunology
Will Jackson Associate Director, Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology

Business Development & Alliances

Matt Bunn Senior Director, Business Development Transactions Monica Anis Director, Global Alliances

HEOR

Alexandra Sharer Associate Director, WW HEOR Markets US, Field Ashley Saunders Associate Director, US HEOR, CAR-T Sumie Kakehi Associate Director, US HEOR, Oncology

Policy & Advocacy

Aakash Patel Director, Cardiovascular & Immunology Policy Chinenye Agim Senior Manager, Patient Advocacy, Oncology Shailee Gusani Associate Director, Executive Branch Strategy

ALUMNI From Other Partner Companies

Medical

Alex Agyei Marfo (Pfizer), Associate Director, Worldwide Medical, Gastroenterology Amber Griffies (Roche) Director, Worldwide Medical Oncology, Medical Communications Christopher Russo (Pfizer) Director, Worldwide Medical, Cendakimab Hiba Malik (J&J) Associate Director, Worldwide Scientific Learning Lead, Lymphoma Irfan Tejani (Sanofi) Senior Director, Worldwide Medical, Oncology John Vaile (Bayer) Executive Director, Global Program Lead Sotyktu Dermatology and GI Natanya Candelario (Roche) Senior Director, Global Health Equity Platform Omama Zubairi (Daiichi Sankyo) Associate Director, Medical Scientist, Oncology Ralu Vlad (Roche) Vice President, Medical Evidence Generation Sapna Patel (Novo Nordisk) Associate Director, Worldwide Medical Oncology, Medical Education

Shalon Jones (Dr. Reddy's Laboratories) Associate Director, Global Medical Affairs, Myeloid

Field Medical

Samantha Kaufman (J&J) Medical Science Liaison, Oncology Sheiva Khavari (Roche) Executive Medical Science Liaison, Rheumatology – Dermatology

Commercial

Akash Lall (Nevakar) Senior Manager, US Commercialization Analytics, Immunology Alberta Drake (Daiichi Sankyo) Associate Director, Worldwide Commercialization Analytics, Cell Therapy, Myeloma/Early Assets

Amanda Bright (Novartis) Associate Director, Acute Myeloid Leukemia Marketing, Hematology Brittny Rule (Bayer) Associate Director, Healthcare Professional - US Marketing, Schizophrenia Jessica Cairns (Roche) Vice President, US Abecma and Franchise Marketing Kevin Crona (Bayer) Associate Director, Business Development Analytics Norhaan (Nora) Khalil (J&J) Senior Manager, US Oncology GU Marketing Tiffany Chow (J&J) Associate Director, Competitive Intelligence, Oncology

Market Access & Pricing

Joseph Lee (J&J) Director, Worldwide PASL Camzyos Karen Shieh (Novo Nordisk) Associate Director, International Markets Lucy Eichenblatt (J&J) Director, Global Market Access and Pricing Strategy, Hematology Parth Vashi (Bayer) Director, Global Market Access and Pricing Strategy, Hematology Samaneh Kalirai (Eli Lilly) Director, Health Systems Analytics

Regulatory Affairs

Andro Shenouda (Merck) Senior Director, Team Leader, Global Regulatory Sciences, Oncology Angela Tang (Roche) Associate Director, Global Scientific and Regulatory Documentation Charles Frost (Roche) Senior Director, Global Scientific and Regulatory Documentation David Nguyen (J&J) Director, Global Regulatory and Safety Sciences Lead, Oncology Jateh Major (Merck) Associate Director, Regulatory Affairs, Oncology Jennifer Dudinak (Roche) Senior Vice President, Head of Global Regulatory Sciences

Kenneth Hu (Sanofi) Senior Manager, Global Regulatory Strategy and Policy, Oncology
 Mark Hanna (Merck) Associate Director, Intercontinental Regulatory Strategy Lead, Oncology
 Matthew Wong (Daiichi-Sankyo) Executive Director, Global Regulatory Strategy,
 Hematology-Oncology

Nitin Kumar (Regeneron) Director, Global Regulatory Lead, Immunology Omar Khalid (Allergan) Senior Director, Team Leader, Regulatory Strategy, Oncology Shih-Yi Kim (J&J) Executive Director, Global Regulatory Strategy, Immunology Vrunda Patel (Bayer) Director, Global Regulatory Strategy and Policy, Immunology and Neuroscience

Commercial Regulatory Affairs

Akshay Patel (Novartis) Associate Director, Commercial Regulatory Affairs Jeff Sniggs (Acorda) Associate Director, Commercial Regulatory Affairs Nicole Stoka (Novartis) Senior Manager, Advertising and Promotion, Commercial Regulatory Affairs

Global Business Operations

Kate Bender (Novartis) Director, Investor Relations

Clinical

Bryan Campbell (Novartis) Senior Vice President, Head of Global Program Leaders, Hematology, Oncology, & Cell Therapy

Gabrielle Guancione (Merck) Associate Director, Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology

Geetha Pudussery (Novartis) Associate Director, Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology

Jennifer Han (Novartis) Senior Mangaer, Clinical Scientist, Early Clinical Development Jennifer Poon (Merck) Director, Clinical Capabilities Lead, Clinical Center of Excellence Jenny Wong (Roche) Senior Director, Global Feasibility Solid Tumor

Jesse Siegel (Merck) Associate Director, Senior Clinical Scientist, Late Global Drug Development Joseph Fiore (Merck) Vice President, Global Program Lead Late Development, Oncology Julia Spiridigliozzi (Merck) Associate Director, Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology

Justin Dennie (Merck) Director, Clinical Science Lead, Oncology Leena Shah (TKL Research) Executive Director, Global Program Lead, Immunology Mackenzie Minogue (J&J) Senior Manager, Clinical Scientist, Early Clinical Development Margee Kyada (Genentech) Associate Director, Senior Clinical Scientist, Clinical R&D Management

Marta Molina (Bimark) Executive Director, Global Program Lead, Eliquis Michelle Hudson (Novartis) Vice President, Global Drug Development Strategic Operations Naomey Sarkis (Novartis) Director, Early Clinical Development, Oncology

Ricky Philipossian (Pfizer) Associate Director, Clinical Scientist, Late Clinical Global Drug Development, Oncology

Ronak Patel (Pfizer) Director, Early Development Project Manager

Sapna Chhagan (Novartis) Executive Director, Early Clinical Development, Cell Therapy Vani Vegesna (Pfizer) Associate Director, Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology

Whitney Handy (Merck) Associate Director, Senior Clinical Scientist, Early Clinical Development

HEOR

Karishma Shelley (TJU/Novartis) Associate Director, Worldwide Markets HEOR, Oncology Laetitia N'Dri (TJU/Novartis) Associate Director, Worldwide Markets HEOR, Immunology Miraj Patel (Sanofi) Director, Worldwide HEOR, Oncology

Policy & Advocacy

Brian Lee (Sanofi) Senior Director, Patient Advocacy, Immunology & Neuroscience Jonathan Naylor (Sanofi) Associate Director, Patient Advocacy, Oncology

*Not an Exhaustive List

* * Last Updated – August 2024



Bristol Myers Squibb Component

The Fellows will become an integral part of their respective teams and will be trained to manage a broad range of responsibilities, similar to those managed by current team members. This fellowship program will necessitate interaction and teamwork with departments in all aspects of the corporation, such as Global Pharmacovigilance and Labeling, Sales, Medical Affairs, Marketing, Regulatory Services, Legal, Clinical Trials, Post-Marketing Clinical Research, and Health Care Channel Management. While at Bristol Myers Squibb, the Fellows will participate in various teambuilding activities and attend leadership development lectures with senior management. Key fellowship activities within Bristol Myers Squibb include:

MENTORSHIP PROGRAM

Participate in a mentorship program with senior management and fellowship alumni to discuss career development, networking, organization structure, market/industry knowledge, etc.

LUNCH AND LEARN SERIES

Attend lunch and learn series with executive sponsors and senior management to have interactive discussions.

BRISTOL MYERS SQUIBB FELLOWSHIP COMMITTEES

Lead and take part in the various fellowship committees such as: Co-Chief Fellows, Recruitment, Community Development, Professional Development, Alumni, and Scholarship committee.





Soaring Ever Higher

Rutgers Pharmaceutical Industry Fellowship (RPIF) Program

Ernest Mario School of Pharmacy (EMSOP) Rutgers, The State University of New Jersey

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Distinguished Professor of the EMSOP, Dr. Carolyn Seyss, the Director for the Institute for Pharmaceutical Industry Fellowships, and Dr. Michael Toscani as the Director Emeritus.



Joseph A. Barone, PharmD, FCCP Dean and Distinguished Professor



Carolyn Seyss, PharmD, RUCIF Fellowship Director



Michael Toscani, PharmD Research Professor, Fellowship Director Emeritus

Program History

EMSOP and 2 pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically- trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the RPIF Program grew significantly and expanded to now include 27 companies within the pharmaceutical and biopharmaceutical industry with approximately 350 Fellows.

Dr. Ernest Mario generously provided an endowment to establish RPIF as an Institute to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- Provide leadership and administrative support
- Promote quality, communication, scholarly activity, and professional development
- Arrange specialized training opportunities within the pharmaceutical and biopharmaceutical industry

RPIF expanded to offer interdisciplinary Fellows' training by adding physician Fellowship opportunities to our well-established program.

2023

2018

The RPIF Certificate is recognized with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow)**.

Over 1,700 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.

Professional Development Series

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the sponsor companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/ commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.



2002

1984

Key Program Features

RPIF FOSTERs the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders.

Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

Rutgers, The State University of New Jersey is one of the major state university systems in the United States. EMSOP is part of Rutgers Health and is the only state school of pharmacy in New Jersey. EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey.

While RPIF offers all the benefits of a large program with an extensive network of distinguished professionals, Fellows receive the individual attention of a small program where they are known and supported as individuals.

F











Family of Leading Companies

Partners include several top global pharmaceutical/biopharmaceutical companies and offer large to small company environments.

Outstanding Alumni Track Record

Over 1,700 alumni hold prominent positions at many leading companies, including VP and C-suite levels.

Strong Network

Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.

Trusted and Proven Since 1984

The Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry for pharmacists as future leaders.

Enhanced Career Development

Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.

Rigorous Academic Component

Rutgers affiliation provides academic and professional development opportunities.

Application Process and Eligibility Requirements

Pharmacy Fellows for the RPIF Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy from an ACPE-accredited institution before July 1 of the fellowship term.

HOW TO APPLY:

The RPIF Program is highly competitive. Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as **October 11, 2024** by visiting our website at: https://pharmafellows.rutgers.edu/how-to-apply/

All application materials must be submitted electronically to the RPIF website per instructions on the site.

REQUIRED ITEMS:	SUBMIT BY:	ADDRESS LOI AND LORS TO	
Application with short-answer questions	October 18th	Joseph A. Barone, PharmD, FCCP Dean and Distinguished Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey 160 Frelinghuysen Road Piscataway, NJ 08854-8020	
Letter of Intent (LOI)	October 18th		
Curriculum Vitae (CV)	October 18th		
Letters of Recommendation (LORs)	December 1st		





"RPIF provides me transformative growth opportunities as I begin my pharmaceutical industry career. The Program's scale offers extensive networking across functional areas, while still delivering personalized attention for Fellows as they partake in opportunities like teaching, research, or committees. Through these opportunities I have developed crucial leadership and communication skills, while also gaining additional tools and connections to thrive in this dynamic field post-fellowship."

Morgan McCluskey Wirtz, PharmD, MBA Medical Communications Fellow RPIF Chief Fellow



"As a Rutgers fellow you'll experience the best of both worlds: the resources and opportunities of a large program combined with the individual support and tight-knit community of a small program. My capacity as both a leader and industry professional has grown immensely since joining— I'd choose RPIF every time!"

REPHARM

Macy Gipson, PharmD Clinical Science, Late Stage Development Fellow RPIF Chief Fellow



"As a Rutgers Fellow, I have had more opportunities through Rutgers and my company than I ever thought possible. The care and kindness of the leadership team and preceptors creates a learning environment that helps fellows flourish and prepare for their careers going forward."

Molly Nelson, PharmD Global Scientific Content- Health Systems Fellow RPIF Chief Fellow







Aligned First Offer Date December 16, 2024

The choice of a Post-Doctoral Industry Fellowship is an important decision. AIFA exists to promote a consensus first offer date for all Fellowship positions. We believe this is a positive reflection of the cultures our Programs offer and that culture is a critical consideration in choice of Fellowship.

We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this aligned offer date.

